The goal of this clinical research study is to learn if the combination of rituximab, lenalidomide, and ibrutinib, when given alone and with standard chemotherapy (called either "EPOCH" - Etoposide, Prednisone, Oncovin [vincristine], Cyclophosphamide, and Hydroxydaunorubicin [doxorubicin]; or "R-CHOP" - Rituximab, Cyclophosphamide, Hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], and Prednisone), can help to control diffuse large B cell lymphoma. The safety of this drug combination will also be studied.